| Disease mongering is now part of the global health debate R Moynihan, E Doran, D Henry PLoS Medicine 5 (5), e106, 2008 | 114 | 2008 |
| Disease mongering: expanding the boundaries of treatable disease E Doran, D Henry Internal medicine journal 38 (11), 858-861, 2008 | 64 | 2008 |
| A prompt to the web: the media and health information seeking behaviour MCB Hogue, E Doran, DA Henry PLoS One 7 (4), e34314, 2012 | 59 | 2012 |
| Empirical uncertainty and moral contest: a qualitative analysis of the relationship between medical specialists and the pharmaceutical industry in Australia E Doran, I Kerridge, P McNeill, D Henry Social science & medicine 62 (6), 1510-1519, 2006 | 59 | 2006 |
| Medical specialists and pharmaceutical industry‐sponsored research: a survey of the Australian experience DA Henry, SR Hill, E Doran, DA Newby, KM Henderson, J Maguire, ... Medical Journal of Australia 182 (11), 557-560, 2005 | 59 | 2005 |
| Moral hazard and prescription medicine use in Australia—the patient perspective E Doran, J Robertson, D Henry Social Science & Medicine 60 (7), 1437-1443, 2005 | 54 | 2005 |
| Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy T Faunce, E Doran, D Henry, P Drahos, A Searles, B Pekarsky, W Neville Globalization and Health 1, 1-10, 2005 | 43 | 2005 |
| Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme A Searles, S Jefferys, E Doran, DA Henry Medical Journal of Australia 187 (4), 236-239, 2007 | 42 | 2007 |
| Ties that bind: multiple relationships between clinical researchers and the pharmaceutical industry D Henry, E Doran, I Kerridge, S Hill, PM McNeill, R Day Archives of internal medicine 165 (21), 2493-2496, 2005 | 39 | 2005 |
| Patient co‐payments and use of prescription medicines E Doran, J Robertson, I Rolfe, D Henry Australian and New Zealand journal of public health 28 (1), 62-67, 2004 | 39 | 2004 |
| Attitudes of physicians and public to pharmaceutical industry ‘gifts’ PU Macneill, IH Kerridge, D Newby, BJ Stokes, E Doran, DA Henry Internal medicine journal 40 (5), 335-341, 2010 | 36 | 2010 |
| Potency, hubris, and susceptibility: The disease mongering critique of pharmaceutical marketing E Doran, C Hogue The Qualitative Report 19 (39), 1, 2014 | 26 | 2014 |
| Australian pharmaceutical policy: price control, equity, and drug innovation in Australia E Doran, D Alexander Henry Journal of Public Health Policy 29, 106-120, 2008 | 26 | 2008 |
| The affordability of prescription medicines in Australia: are copayments and safety net thresholds too high? A Searles, E Doran, TA Faunce, D Henry Australian Health Review 37 (1), 32-40, 2012 | 24 | 2012 |
| Dilemmas in the compassionate supply of investigational cancer drugs JRR Lewis, W Lipworth, I Kerridge, E Doran Internal Medicine Journal 44 (9), 841-845, 2014 | 23 | 2014 |
| Mixed method integrative review exploring nurses’ recognition and response to unsafe practice W Blair, A Kable, H Courtney‐Pratt, E Doran Journal of Advanced Nursing 72 (3), 488-500, 2016 | 18 | 2016 |
| Managing ethical issues in patient care and the need for clinical ethics support E Doran, J Fleming, C Jordens, CL Stewart, J Letts, IH Kerridge Australian Health Review 39 (1), 44-50, 2014 | 18 | 2014 |
| The PBS community awareness campaign: how helpful is blaming patients? E Doran, DA Henry Medical journal of Australia 179 (10), 544-546, 2003 | 18 | 2003 |
| Clinical ethics support in contemporary health care E Doran, I Kerridge, C Jordens, AJ Newson The Oxford handbook of health care management, 164-187, 2016 | 17 | 2016 |
| Australia's pharmaceutical cost sharing policy: reducing waste or affordability? E Doran, J Robertson Australian Health Review 33 (2), 231-240, 2009 | 12 | 2009 |
